US009409907B2

(12) **United States Patent**
Hoelder et al.

(10) **Patent No.: US 9,409,907 B2**
(45) **Date of Patent: Aug. 9, 2016**

(54) **INHIBITOR COMPOUNDS**

(71) Applicant: **Cancer Research Technology Limited**, London (GB)

(72) Inventors: **Swen Hoelder**, London (GB); **Julian Blagg**, London (GB); **Savade Solanki**, London (GB); **Hannah Woodward**, London (GB); **Sebastien Naud**, London (GB); **Vassilios Bavetsias**, London (GB); **Peter Sheldrake**, London (GB); **Paolo Innocenti**, London (GB); **Kwai-Ming J. Cheung**, London (GB); **Butrus Atrash**, London (GB)

(73) Assignee: **Cancer Research Technology Limited**, London (GB)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **14/426,549**

(22) PCT Filed: **Sep. 9, 2013**

(86) PCT No.: **PCT/GB2013/052360**

§ 371 (c)(1),
(2) Date: **Mar. 6, 2015**

(87) PCT Pub. No.: **WO2014/037750**

PCT Pub. Date: **Mar. 13, 2014**

(65) **Prior Publication Data**

US 2015/0239884 A1 Aug. 27, 2015

(30) **Foreign Application Priority Data**

Sep. 7, 2012 (GB) 1216017.2

(51) **Int. Cl.**

A01N 43/90	(2006.01)
A61K 31/519	(2006.01)
C07D 471/00	(2006.01)
C07D 487/00	(2006.01)
C07D 471/04	(2006.01)
C07D 401/14	(2006.01)
C07D 413/14	(2006.01)
C07D 401/04	(2006.01)
C07D 405/04	(2006.01)
C07D 519/00	(2006.01)

(52) **U.S. Cl.**

CPC ***C07D 471/04*** (2013.01); ***C07D 401/04*** (2013.01); ***C07D 401/14*** (2013.01); ***C07D 405/04*** (2013.01); ***C07D 413/14*** (2013.01); ***C07D 519/00*** (2013.01)

(58) **Field of Classification Search**

None

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

2,697,710	A	12/1954	Hitchings et al.
3,021,332	A	2/1962	Hitchings et al.
2003/0073668	A1	4/2003	Booth et al.
2003/0105115	A1	6/2003	Metcalf et al.
2004/0092521	A1	5/2004	Altenbach et al.
2005/0256118	A1	11/2005	Altenbach et al.
2005/0272728	A1	12/2005	Altenbach et al.
2011/0257196	A1	10/2011	Lu et al.
2015/0031672	A1	1/2015	Ren et al.

FOREIGN PATENT DOCUMENTS

WO	WO-9615128	A2	5/1996
WO	WO-01/55147	A1	8/2001
WO	WO-02090360	A1	11/2002
WO	WO-03/051366	A2	6/2003
WO	WO-03074530	A1	9/2003
WO	WO-2004/043458	A1	5/2004
WO	WO-2004065378	A1	8/2004
WO	WO-2007/000240	A1	1/2007
WO	WO-2007/125405	A2	11/2007
WO	WO-2007/140222	A2	12/2007
WO	WO-2008/135232	A1	11/2008
WO	WO-2009/032694	A1	3/2009
WO	WO-2009/103966	A1	8/2009
WO	WO-2010/007374	A1	1/2010
WO	WO-2010/129816	A2	11/2010

(Continued)

OTHER PUBLICATIONS

Balog et al., "Novel fluorescent isoquinoline derivatives obtained via Buchwald-Hartwig coupling of isoquinolin-3-amines", *Arkivoc*, vol. 5, 109-119 (2012).

(Continued)

Primary Examiner — Jeffrey H Murray

(74) *Attorney, Agent, or Firm* — Foley Hoag LLP; David P. Halstead

(57) **ABSTRACT**

The present invention relates to compounds of formula I

I



wherein R_1, R_4, Ar, W, X and Z are all as defined herein. The compounds of the present invention are known to inhibit the spindle checkpoint function of Monospindle 1 (Mps1—also known as TTK) kinases either directly or indirectly via interaction with the Mps1 kinase itself. In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.

2 Claims, No Drawings